Wednesday, July 8, 2026
🇺🇸 FDA

biotech · Breast Cancer · Advanced Breast Cancer · PBYI

PUMA BIOTECHNOLOGY

PUMA BIOTECHNOLOGY, INC.

PUMA BIOTECHNOLOGY clinical programs — 40 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
10880 Wilshire Blvd, Los Angeles, CA 90024, US HQ
2010 Founded
257 Employees
Public company Type
PBYI · NYSE Ticker
Company details
Status
Public
HQ
10880 Wilshire Blvd, Los Angeles, CA 90024, US
Founded
2010
Employees
257
Programs
40
Drugs
23
Patents
1
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

PUMA BIOTECHNOLOGY projects

40 ClinicalTrials.gov programs sponsored by PUMA BIOTECHNOLOGY.

PUMA BIOTECHNOLOGY has 40 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

40 programs

Clinical programs

  1. neratinib

    PUMA BIOTECHNOLOGY, INC.

    HER2+ Metastatic Breast Cancer (MBC)

    phase 3 small molecule completed

    1 trial

  2. Alisertib

    PUMA BIOTECHNOLOGY, INC.

    Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  3. Alisertib

    PUMA BIOTECHNOLOGY, INC.

    Small Cell Lung Cancer ( SCLC )

    phase 2 small molecule active

    1 trial

  4. Alisertib

    PUMA BIOTECHNOLOGY, INC.

    Hormone Receptor Positive HER-2 Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  5. Capecitabine

    PUMA BIOTECHNOLOGY, INC.

    Breast Cancer

    phase 2 small molecule active

    1 trial

  6. HKI-272

    PUMA BIOTECHNOLOGY, INC.

    Advanced Breast Cancer

    phase 2 small molecule completed

    2 trials

  7. HKI-272

    PUMA BIOTECHNOLOGY, INC.

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  8. HKI-272

    PUMA BIOTECHNOLOGY, INC.

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule completed

    1 trial

  9. NERATINIB

    PUMA BIOTECHNOLOGY, INC.

    Stage IV (Metastatic) Breast Cancer

    phase 2 small molecule terminated

    1 trial

  10. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    HER2 Amplified Breast Cancer

    phase 2 small molecule completed

    1 trial

  11. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Advanced Breast Cancer

    phase 2 small molecule completed

    1 trial

  12. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Anatomic Stage I Breast Cancer

    phase 2 small molecule active

    1 trial

  13. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Breast Cancer

    phase 2 small molecule completed

    8 trials

  14. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Early-stage Breast Cancer

    phase 2 small molecule active

    1 trial

  15. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Early Stage HER2+ Breast Cancer

    phase 2 small molecule completed

    1 trial

  16. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    GastroEsophageal Cancer

    phase 2 small molecule active

    1 trial

  17. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    HER2-positive Breast Cancer

    phase 2 small molecule completed

    1 trial

  18. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Metastatic Breast Cancer

    phase 2 small molecule terminated

    1 trial

  19. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Metastatic Prostate Adenocarcinoma

    phase 2 small molecule terminated

    1 trial

  20. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Solid Tumor, Adult

    phase 2 small molecule active

    1 trial

  21. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

    phase 2 small molecule terminated

    1 trial

  22. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  23. PUMA-ALI-1201

    PUMA BIOTECHNOLOGY, INC.

    Hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) recurrent or metastatic breast cancer (MBC)

    phase 2 small molecule active

    1 trial

  24. Paclitaxel

    PUMA BIOTECHNOLOGY, INC.

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  25. Temozolomide

    PUMA BIOTECHNOLOGY, INC.

    Glioblastoma

    phase 2 small molecule active

    1 trial

  26. Temsirolimus

    PUMA BIOTECHNOLOGY, INC.

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  27. Trastuzumab

    PUMA BIOTECHNOLOGY, INC.

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  28. neratinib

    PUMA BIOTECHNOLOGY, INC.

    HER2-mutant Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  29. neratinib

    PUMA BIOTECHNOLOGY, INC.

    Breast Neoplasms

    phase 2 small molecule completed

    3 trials

  30. Digoxin

    PUMA BIOTECHNOLOGY, INC.

    Healthy

    phase 1 small molecule completed

    1 trial

  31. Lansoprazole

    PUMA BIOTECHNOLOGY, INC.

    Healthy

    phase 1 small molecule completed

    1 trial

  32. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Healthy Subjects

    phase 1 small molecule completed

    3 trials

  33. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Neoplasms

    phase 1 small molecule completed

    1 trial

  34. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Advanced Malignant Solid Tumors

    phase 1 small molecule completed

    3 trials

  35. Neratinib (HKI-272)

    PUMA BIOTECHNOLOGY, INC.

    Hepatic Insufficiency

    phase 1 small molecule completed

    1 trial

  36. Neratinib 160 mg

    PUMA BIOTECHNOLOGY, INC.

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  37. Neratinib Pill

    PUMA BIOTECHNOLOGY, INC.

    Gastric Cancer

    phase 1 small molecule active

    1 trial

  38. Osimertinib

    PUMA BIOTECHNOLOGY, INC.

    Lung Cancer Metastatic

    phase 1 small molecule active

    1 trial

  39. neratinib

    PUMA BIOTECHNOLOGY, INC.

    Healthy

    phase 1 small molecule completed

    5 trials

  40. neratinib

    PUMA BIOTECHNOLOGY, INC.

    Tumors

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does PUMA BIOTECHNOLOGY have?

40 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.